Some NSCLC subsets have been shown to express PDL-1, but those with positive PDL-1 and higher numbers of CD8+ tumor-infiltrating lymphocytes (TILs)—conventionally referred to as “hot tumors”—had a better objective response rate (ORR) with combination therapy of PD-1 inhibitors, CIK cells, and chemotherapy [30]. The gene discussed is CD8A; the disease is neoplasm.